Singapore’s sovereign wealth fund GIC has participated in a consortium of institutional investors, led by Hillhouse Capital Group, to invest $418 million through a private placement in Nasdaq-listed Chinese biopharma company I-Mab, according to a GIC press release.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
